查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589281

大丽花疾病药物市场：按治疗类型、药物、分销管道和最终用户划分 - 全球预测 2025-2030

Darier Disease Drugs Market by Treatment Type (Medication, Surgery), Drugs (Oral Retinoids, Topical Retinoids), Distribution Channel, End- User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年大丽花疾病治疗市值为771.2亿美元，预计到2024年将达到815.8亿美元，复合年增长率为6.18%，预计到2030年将达到1173.6亿美元。

毛囊角化病，又称毛囊角化病，是一种罕见的遗传性皮肤病，其特征是身体上出现疣状斑点。考虑到缺乏明确的治疗方法，大丽花疾病治疗药物市场主要集中在控制症状的治疗选择。局部和全身治疗的目标是减轻皮肤病变的严重程度、控制感染疾病和缓解搔痒，通常会结合生活方式和饮食建议。对此类治疗的需求正在增加，因为这种疾病是终生的并且会影响个人的生活品质。市场的应用范围包括类类视色素A和皮质类固醇等组合药物、非处方药、基因治疗和新配方研究。

主要市场统计
基准年[2023] 771.2亿美元
预测年份 [2024] 815.8亿美元
预测年份 [2030] 1173.6亿美元
复合年增长率（%） 6.18%

该市场的成长要素包括持续的研发活动、对罕见疾病的认识不断提高以及皮肤科领域的进步。诊断工具的改进也促进了早期检测和治疗，进一步支持市场成长。潜在的机会包括利用基因组学的突破来开发生技药品和个人化医疗方法。抓住这些机会的研究包括与基因研究人员合作以及利用数位平台扩大病人参与。

儘管有这些机会，市场仍面临一些限制，例如药物开发高成本、监管障碍以及由于患者群体有限而对罕见疾病进行临床测试带来的挑战。此外，大众和一些医疗专业人员对大丽花病缺乏认识和了解，阻碍了诊断和治疗。

在创新和研究方面，对 CRISPR 等基因编辑技术的投资是一个很有前景的领域，它为遗传疾病提供了治疗潜力。扩大与皮肤科诊所的合作伙伴关係，进行以患者为中心的研究并加强对患者教育的关注，可能会深入了解疾病进展和更有针对性的治疗方法。儘管市场的本质仍然是利基市场，但透过精准医学和治疗方法的进步实现成长的途径前景广阔。

市场动态：揭示快速发展的大丽花疾病药物市场的关键市场洞察

大丽花病药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 各国大丽花病的高风险
    • 加大开发新药研发投入
    • 消费者意识不断增强
  • 市场限制因素
    • 大丽花病药物的报销限制
  • 市场机会
    • 治疗毛里尔病的新型皮肤病製剂的出现
    • 完善供应链，强化药品供应体系
  • 市场问题
    • 治疗的复杂性和持续时间

波特的五力：驾驭大丽花疾病药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解大丽花病药物市场的外部影响

外部宏观环境因素在塑造大丽花疾病治疗药物市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解大丽花疾病治疗药物市场的竞争状况

对大丽花疾病治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵：大丽花疾病治疗药物市场供应商的绩效评估

FPNV 定位矩阵是评估大丽花疾病治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製大丽花疾病药物市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对大丽花疾病治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

它也回答重要问题，帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 经济体中出现达里尔氏症的高风险
      • 加大开发新药研发投入
      • 意识提升
    • 抑制因素
      • 大丽花病药物的有限退款
    • 机会
      • 针对达里尔病的新型皮肤病製剂的出现
      • 改善供应链以增加药品可得性
    • 任务
      • 治疗的复杂性和持续时间
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章大丽花疾病治疗药物市场：依治疗类型

  • 介绍
  • 药品
  • 外科手术

第七章 大丽花疾病治疗药物市场：依药物分类

  • 介绍
  • 口服类视色素
  • 局部类视色素

第八章大丽花疾病治疗药物市场：依通路分类

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第九章大丽花疾病治疗药物市场：依最终使用者分类

  • 介绍
  • 皮肤科医生
  • 居家医疗
  • 医院
  • 专科诊所

第十章 北美和南美大丽花疾病治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太大丽花疾病药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲大丽花病药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Allergan plc
  • Bausch Health Companies Inc.
  • BridgeBio Inc
  • Galderma Laboratories, LP
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Inc
  • Mayne Pharma Group Limited
  • Merck KGaA
  • Nimble Pharmaceuticals
  • Novartis AG
  • Recursion Pharmaceuticals, Inc.
  • Sigmapharm Laboratories, LLC
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd
  • TOLMAR Inc.
Product Code: MRR-4659C8712C78

The Darier Disease Drugs Market was valued at USD 77.12 billion in 2023, expected to reach USD 81.58 billion in 2024, and is projected to grow at a CAGR of 6.18%, to USD 117.36 billion by 2030.

Darier Disease, also known as keratosis follicularis, is a rare, genetic skin disorder characterized by wart-like blemishes on the body. The Darier Disease drugs market focuses on treatment options that primarily manage symptoms, considering there is no definitive cure. The scope encompasses topical and systemic treatments intended to reduce the severity of skin lesions, manage infections, and alleviate itchiness, with products often used in conjunction with lifestyle and dietary recommendations. The necessity for such treatments is growing owing to the disease's life-long persistence and potential impact on individuals' quality of life. Applications in this market range from prescription medications such as retinoids and corticosteroids to over-the-counter solutions and ongoing research into gene therapy and novel drug formulations.

KEY MARKET STATISTICS
Base Year [2023] USD 77.12 billion
Estimated Year [2024] USD 81.58 billion
Forecast Year [2030] USD 117.36 billion
CAGR (%) 6.18%

The key influencing growth factors in this market include ongoing R&D activities, increasing awareness about rare diseases, and advancements in dermatological science. Improved diagnostic tools also facilitate early detection and treatment, further fueling market growth. One potential opportunity is the development of biologics and personalized medicine approaches, leveraging breakthroughs in genomics. Recommendations to seize these opportunities include collaborations with genetic researchers and leveraging digital platforms for broader patient engagement.

Despite these opportunities, the market faces limitations such as the high cost of drug development, regulatory hurdles, and the challenges associated with conducting clinical trials for rare diseases due to limited patient populations. Moreover, there is a lack of awareness and understanding of Darier Disease among the general public and some healthcare professionals, which can hinder diagnosis and treatment.

For innovation and research, investing in gene-editing technologies like CRISPR, which offers potential therapy for genetic disorders, stands out as a promising area. Expanding partnerships with dermatology clinics to conduct patient-centric research and increasing the focus on patient education could provide insights into the disease's progression and better-targeted treatments. The market's nature remains niche, but with promising avenues for growth through precision medicine and therapeutic advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Darier Disease Drugs Market

The Darier Disease Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High risk of Darier diseases in economies
    • Rising investments in R&D to develop novel drugs
    • Increasing awareness among consumers
  • Market Restraints
    • Limited reimbursement for Darier disease drugs
  • Market Opportunities
    • Emergence of novel dermatological preparations for Darier disorders
    • Improvements in the supply chain to enhance the availability of drugs
  • Market Challenges
    • Complexity and prolonged nature of treatment

Porter's Five Forces: A Strategic Tool for Navigating the Darier Disease Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Darier Disease Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Darier Disease Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Darier Disease Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Darier Disease Drugs Market

A detailed market share analysis in the Darier Disease Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Darier Disease Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Darier Disease Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Darier Disease Drugs Market

A strategic analysis of the Darier Disease Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Darier Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include Allergan plc, Bausch Health Companies Inc., BridgeBio Inc, Galderma Laboratories, L.P, GlaxoSmithKline plc, Glenmark Pharmaceuticals Inc, Mayne Pharma Group Limited, Merck KGaA, Nimble Pharmaceuticals, Novartis AG, Recursion Pharmaceuticals, Inc., Sigmapharm Laboratories, LLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, and TOLMAR Inc..

Market Segmentation & Coverage

This research report categorizes the Darier Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Medication and Surgery.
  • Based on Drugs, market is studied across Oral Retinoids and Topical Retinoids.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on End- User, market is studied across Dermatologist, Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High risk of Darier diseases in economies
      • 5.1.1.2. Rising investments in R&D to develop novel drugs
      • 5.1.1.3. Increasing awareness among consumers
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement for Darier disease drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of novel dermatological preparations for Darier disorders
      • 5.1.3.2. Improvements in the supply chain to enhance the availability of drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity and prolonged nature of treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Darier Disease Drugs Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medication
  • 6.3. Surgery

7. Darier Disease Drugs Market, by Drugs

  • 7.1. Introduction
  • 7.2. Oral Retinoids
  • 7.3. Topical Retinoids

8. Darier Disease Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Darier Disease Drugs Market, by End- User

  • 9.1. Introduction
  • 9.2. Dermatologist
  • 9.3. Homecare
  • 9.4. Hospitals
  • 9.5. Specialty Clinics

10. Americas Darier Disease Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Darier Disease Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Darier Disease Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Allergan plc
  • 2. Bausch Health Companies Inc.
  • 3. BridgeBio Inc
  • 4. Galderma Laboratories, L.P
  • 5. GlaxoSmithKline plc
  • 6. Glenmark Pharmaceuticals Inc
  • 7. Mayne Pharma Group Limited
  • 8. Merck KGaA
  • 9. Nimble Pharmaceuticals
  • 10. Novartis AG
  • 11. Recursion Pharmaceuticals, Inc.
  • 12. Sigmapharm Laboratories, LLC
  • 13. Sun Pharmaceutical Industries Ltd.
  • 14. Teva Pharmaceutical Industries Ltd
  • 15. TOLMAR Inc.

LIST OF FIGURES

  • FIGURE 1. DARIER DISEASE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DARIER DISEASE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DARIER DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DARIER DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DARIER DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DARIER DISEASE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY ORAL RETINOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY TOPICAL RETINOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DERMATOLOGIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 190. DARIER DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. DARIER DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023